Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Brii Bio Expands Rights for VBI’s HBV Therapy to Global in $437 Million Deal

publication date: Jul 6, 2023

Beijing Brii Bio signed an expanded global license to an HBV immunotherapeutic therapy developed by VBI Vaccines for $15 million in near-term payments plus $422 million in milestones. VBI is also eligible for royalties. Brii originally acquired China rights to the vaccine soon after it was formed in 2018. Brii believes BRII-179 will become part of a combination therapy that causes a strong response, creating a functional cure for HBV. As part of the deal, Brii will also acquire rights from VBI to develop and commercialize a HBV prophylactic vaccine, PreHevbri®, in Greater China and Asia Pacific countries. More details....

Stock Symbol: (HK: 2137)

Share this with colleagues:  

 


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital